Protalix BioTherapeutics, Inc.
PLX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001006281
No open-market purchases or sales by Protalix BioTherapeutics, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $33.7M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Protalix BioTherapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Of which not filed for Q4 2021 | Q4 2021 | Change |
|---|---|---|---|---|
| Holders | 35 | 1 | 31 | −3 |
| Shares | 4.42M | 6.00K | 2.94M | −1.47M (−33.4%) |
| Value | $5.91M | $8.00K | $2.45M | −$3.45M (−58.5%) |
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (8)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Commonwealth Equity Services, LLC | 40,290 | $33.0K | 0.00% |
| Virtu Financial LLC | 18,371 | $15.0K | 0.00% |
| Finivi Inc. | 14,544 | $12.1K | 0.01% |
| TD Waterhouse Canada Inc. | 6,000 | $5.76K | 0.00% |
| National Bank of Canada | 6,000 | $5.00K | 0.00% |
| Tower Research Capital LLC (TRC) | 72 | $0 | 0.00% |
| Rinkey Investments | 100 | $0 | 0.00% |
| Snowden Capital Advisors LLC | 500 | $0 | 0.00% |
Sold out (11)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Meitav Dash Investments Ltd | 244,332 | $325.0K |
| Walleye Capital LLC | 220,089 | $293.0K |
| Simplex Trading, LLC | 69,049 | $129.0K |
| Walleye Trading LLC | 81,000 | $108.0K |
| Bridgeway Capital Management, LLC | 58,890 | $78.0K |
| Credit Suisse AG | 31,974 | $43.0K |
| Wolverine Trading, LLC | 28,168 | $39.0K |
| XTX Topco Ltd | 20,514 | $27.0K |
| JPMorgan Chase & Co | 5,847 | $8.00K |
| Harbour Investments, Inc. | 3,000 | $4.00K |
| Steward Partners Investment Advisory, LLC | 1,000 | $1.00K |
Not filed for Q4 2021 yet (1)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Psagot Investment House Ltd. | 6,000 | $8.00K |